Kallikrein protease activated receptor (PAR) axis: An attractive target for drug development

Journal of Medicinal Chemistry

Volumn 55, Issue 15, 2012, Pages 6669-6686

  Caliendo, Giuseppe ^a   Santagada, Vincenzo ^a   Perissutti, Elisa ^a   Severino, Beatrice ^a   Fiorino, Ferdinando ^a   Frecentese, Francesco ^a   Juliano, Luiz ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZAMIDINE; 8,8' PAEPALANTINE; ANTIPAIN; APROTININ; AZAINDOLE DERIVATIVE; BENZAMIDINE DERIVATIVE; BENZENE; BENZIMIDAZOLE; BENZOXAZINONE DERIVATIVE; BENZYLSULFONYL FLUORIDE; CHLOROMETHYLKETONE DERIVATIVE; CHYMOSTATIN; DYFLOS; ISOCOUMARIN DERIVATIVE; KALLIKREIN; KALLIKREIN INHIBITOR; KETONE DERIVATIVE; LEUPEPTIN; NAPHTHALENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR; SMALL MOLECULE TRANSPORT AGENT; SOYBEAN TRYPSIN INHIBITOR; SULFONIC ACID DERIVATIVE; THIAZOLE DERIVATIVE; TOSYLPHENYLCHLOROMETHYLKETONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIOXANTHIN; [6 AMINOPYRIDIN 3 YL)METHYL]AMIDE DERIVATIVE;

BIOLOGICAL ACTIVITY; DRUG ACTIVITY; DRUG DESIGN; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; INFLAMMATION; NEOPLASM; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; STRUCTURE ACTIVITY RELATION;

EID: 84864917801     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300407t     Document Type: Review

References (179)

1. Travis, J.; Potempa, J.; Maeda, H. Are bacterial proteinases pathogenic factors? Trends Microbiol. 1995, 3, 405-407
2. Klemba, M.; Goldberg, D. E. Biological roles of proteases in parasitic protozoa Annu. Rev. Biochem. 2002, 71, 275-305
3. Monod, M.; Capoccia, S.; Lechenne, B.; Zaugg, C.; Holdom, M.; Jousson, O. Secreted proteases from pathogenic fungi Int. J. Med. Microbiol. 2002, 292, 405-419
4. Tong, L. Viral proteases Chem. Rev. 2002, 102, 4609-4626
5. Puente, X. S.; Sanchez, L. M.; Overall, C. M.; Lopez-Otin, C. Human and mouse proteases: a comparative genomic approach Nat. Rev. Genet. 2003, 4, 544-558
6. Yousef, G. M.; Kopolovic, A. D.; Elliott, M. B.; Diamandis, E. P. Genomic overview of serine proteases Biochem. Biophys. Res. Commun. 2003, 305, 28-36
7. López-Otín, C.; Matrisian, L. M. Emerging roles of proteases in tumour suppression Nat. Rev. Cancer 2007, 7, 800-808
8. Barrett, A. J.; Rawlings, N. D.; Woessner, J. F. Handbook of Proteolytic Enzymes, 2 nd ed.; Elsevier Academic Press: San Diego, CA, 2004.
9. Mason, A. J.; Evans, B. A.; Cox, D. R.; Shine, J.; Richards, R. I. Structure of mouse kallikrein gene family suggests a role in specific processing of biologically active peptides Nature 1983, 303, 300-307
10. Fukushima, D.; Kitamura, N.; Nakanishi, S. Nucleotide sequence of cloned cDNA for human pancreatic kallikrein Biochemistry 1985, 24, 8037-8043
11. Schedlich, L. J.; Bennetts, B. H.; Morris, B. J. Primary structure of a human glandular kallikrein gene DNA 1987, 6, 429-437
12. Lundwall, A.; Lilja, H. Molecular cloning of human prostate specific antigen cDNA FEBS Lett. 1987, 214, 317-322
13. Gan, L.; Lee, I.; Smith, R.; Argonza-Barrett, R.; Lei, H.; McCuaig, J.; Moss, P.; Paeper, B.; Wang, K. Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region Gene 2000, 257, 119-130
14. Harvey, T. J.; Hooper, J. D.; Myers, S. A.; Stephenson, S. A.; Ashworth, L. K.; Clements, J. A. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4 J. Biol. Chem. 2000, 275, 37397-37406
15. Yousef, G. M.; Chang, A.; Scorilas, A.; Diamandis, E. P. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4 Biochem. Biophys. Res. Commun. 2000, 276, 125-133
16. Yousef, G. M.; Luo, L. Y.; Scherer, S. W.; Sotiropoulou, G.; Diamandis, E. P. Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease Genomics 2000, 62, 251-259
17. Borgono, C. A.; Diamandis, E. P. The emerging roles of human tissue kallikreins in cancer Nat. Rev. Cancer 2004, 4, 876-890
18. Yousef, G. M.; Diamandis, E. P. The new human tissue kallikrein gene family: structure, function, and association to disease Endocr. Rev. 2001, 22, 184-204
19. Lundwall, A.; Band, V.; Blaber, M.; Clements, J. A.; Courty, Y.; Diamandis, E. P.; Fritz, H.; Lilja, H.; Malm, J.; Maltais, L. J.; Olsson, A. Y.; Petraki, C.; Scorilas, A.; Sotiropoulou, G.; Stenman, U. H.; Stephan, C.; Talieri, M.; Yousef, G. M. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins Biol. Chem. 2006, 387, 637-641
20. Borgono, C. A.; Michael, I. P.; Diamandis, E. P. Human tissue kallikreins: physiologic roles and applications in cancer Mol. Cancer Res. 2004, 2, 257-280
21. Evans, B. A.; Drinkwater, C. C.; Richards, R. I. Mouse glandular kallikrein genes. Structure and partial sequence analysis of the kallikrein gene locus J. Biol. Chem. 1987, 262, 8027-8034
22. Wines, D. R.; Brady, J. M.; Southard, E. M.; MacDonald, R. J. Evolution of the rat kallikrein gene family: gene conversion leads to functional diversity J. Mol. Evol. 1999, 32, 476-492
23. Kurlender, L.; Borgono, C.; Michael, I. P.; Obiezu, C.; Elliott, M. B.; Yousef, G. M.; Diamandis., E. P. A survey of alternative transcripts of human tissue kallikrein genes Biochim. Biophys. Acta 2005, 1755, 1-14
24. Chagas, J. R.; Hirata, I. Y.; Juliano, M. A.; Xiong, W.; Wang, C.; Chao, J.; Juliano, L.; Prado, E. S. Substrate specificities of tissue kallikrein and T-kininogenase: their possible role in kininogen processing Biochemistry 1992, 31, 4969-4974
25. Zani, M.; Brillard-Bourdet, M.; Lazure, C.; Juliano, L.; Courty, Y.; Gauthier, F.; Moreau, T. Purification and characterization of active recombinant rat kallikrein rK9 Biochim. Biophys. Acta 2001, 1547, 387-396
26. El Moujahed, A.; Brillard-Bourdet, M.; Juliano, M. A.; Moreau, T.; Chagas, J. R.; Gutman, N.; Prado, E. S.; Gauthier, F. Kininogen-derived fluorogenic substrates for investigating the vasoactive properties of rat tissue kallikreins. Identification of a T-kinin-releasing rat kallikrein Eur. J. Biochem. 1997, 247, 652-658
27. Fogaca, S. E.; Melo, R. L.; Pimenta, D. C.; Hosoi, K.; Juliano, L.; Juliano, M. A. Differences in substrate and inhibitor sequence specificity of human, mouse and rat tissue kallikreins Biochem. J. 2004, 380, 775-781
28. Lundwall, A.; Brattsand, M. Kallikrein-related peptidases Cell. Mol. Life Sci. 2008, 65, 2019-2038
29. Sotiropoulou, G.; Pampalakis, G.; Diamandis, E. P. Functional roles of human kallikrein-related peptidases J. Biol. Chem. 2009, 284, 32989-32994
30. Angelo, P. F.; Lima, A. R.; Alves, F. M.; Blaber, S. I.; Scarisbrick, I. A.; Blaber, M.; Juliano, L.; Juliano, M. A. Substrate specificity of human kallikrein 6: salt and glycosaminoglycan effects J. Biol. Chem. 2006, 281, 3116-3126
31. Andrade, D.; Assis, D. M.; Santos, J. A. N.; Alves, F. M.; Hirata, Y. I.; Araujo, M. S.; Blaber, S. I.; Blaber, M.; Juliano, M. A.; Juliano, L. Substrate specificity of kallikrein-related peptidase 13 activated by salts or glycosaminoglycans and a search for natural substrate candidates Biochimie 2011, 93, 1701-1709
32. Andrade, D.; Assis, D. M.; Lima, A. R.; Oliveira, J. R.; Araujo, M. S.; Blaber, S. I.; Blaber, M.; Juliano, M. A.; Juliano, L. Substrate specificity and inhibition of human kallikrein-related peptidase 3 (KLK3 or PSA) activated with sodium citrate and glycosaminoglycans Arch. Biochem. Biophys. 2010, 498, 74-82
33. Fiedler, F.; Leysath, G. Substrate specificity of porcine pancreatic kallikrein Adv. Exp. Med. Biol. 1979, 120, 261-271
34. Axen, R.; Gross, E.; Witkop, B.; Pierce, J. V.; Webster, M. E. Release of kinin activity from human kininogens and fresh plasma by cyanogen bromide Biochem. Biophys. Res. Commun. 1966, 5, 353-357
35. Chagas, J. R.; Portaro, F. C.; Hirata, I. Y.; Almeida, P. C.; Juliano, M. A.; Juliano, L.; Prado, E. S. Determinants of the unusual cleavage specificity of lysyl-bradykinin-releasing kallikreins Biochem. J. 1995, 306, 63-69
36. Del Nery, E.; Chagas, J. R.; Juliano, M. A.; Prado, E. S.; Juliano, L. Evaluation of the extent of the binding site in human tissue kallikrein by synthetic substrates with sequences of human kininogen fragments Biochem. J. 1995, 312, 233-238
37. Pimenta, D. C.; Chao, J.; Chao, L.; Juliano, M. A.; Juliano, L. Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids Biochem. J. 1999, 339, 473-479
38. Melo, R. L.; Barbosa Pozzo, R. C.; Pimenta, D. C.; Perissutti, E.; Caliendo, G.; Santagada, V.; Juliano, L.; Juliano, M. A. Human tissue kallikrein S1 subsite recognition of non-natural basic amino acids Biochemistry 2001, 40, 5226-5232
39. Bourgeois, L.; Brillard-Bourdet, M.; Deperthes, D.; Juliano, M. A.; Juliano, L.; Tremblay, R. R.; Dube, J. Y.; Gauthier, F. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation J. Biol. Chem. 1997, 272, 29590-29595
40. Rehault, S.; Brillard-Bourdet, M.; Bourgeois, L.; Frenette, G.; Juliano, L.; Gauthier, F.; Moreau, T. Design of new and sensitive fluorogenic substrates for human kallikrein hK3 (prostate-specific antigen) derived from semenogelin sequences Biochim. Biophys. Acta 2002, 1596, 55-62
41. Huang, X.; Knoell, C. T.; Frey, G.; Hazegh-Azam, M.; Tashjian, A. H.; Hedstrom, L.; Abeles, R. H.; Timasheff, S. N. Modulation of recombinant human prostate-specific antigen: activation by hofmeister salts and inhibition by azapeptides Biochemistry 2001, 40, 11734-11741
42. Rehault, S.; Monget, P.; Mazerbourg, S.; Tremblay, R.; Gutman, N.; Gauthier, F.; Moreau, T. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3 Eur. J. Biochem. 2001, 268, 2960-2968
43. Debela, M.; Beaufort, N.; Magdolen, V.; Schechter, N. M.; Craik, C. S.; Schmitt, M.; Bode, W.; Goettig, P. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7 Biol. Chem. 2008, 389 (6) 623-632
44. Luo, L. Y.; Jiang, W. Inhibition profiles of human tissue kallikreins by serine protease inhibitors Biol. Chem. 2006, 387, 813-816
45. Zhou, G. X.; Chao, L.; Chao, J. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence J. Biol. Chem. 1992, 267, 25873-25880
46. Obiezu, C. V.; Diamandis, E. P. Human tissue kallikrein gene family: applications in cancer Cancer Lett. 2005, 224, 1-22
47. Williams, S. A.; Singh, P.; Isaacs, J. T.; Denmeade, S. R. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007, 67, 312-329
48. Fritzsche, F.; Gansukh, T.; Borgono, C. A.; Burkhardt, M.; Pahl, S.; Mayordomo, E.; Winzer, K. J.; Weichert, W.; Denkert, C.; Jung, K.; Stephan, C.; Dietel, M.; Diamandis, E. P.; Dahl, E.; Kristiansen, G. Expression of human kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status Br. J. Cancer 2006, 94, 540-547
49. Xi, Z.; Kaern, J.; Davidson, B.; Klokk, T. I.; Risberg, B.; Tropé, C.; Saatcioglu, F. Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer Gynecol Oncol. 2004, 94, 80-85
50. Talieri, M.; Diamandis, E. P.; Gourgiotis, D.; Mathioudaki, K.; Scorilas, A. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma Thromb. Haemostasis 2004, 91, 180-186
51. Holzscheiter, L.; Biermann, J. C.; Kotzsch, M.; Prezas, P.; Farthmann, J.; Baretton, G.; Luther, T.; Tjan-Heijnen, V. C.; Talieri, M.; Schmitt, M.; Sweep, F. C.; Span, P. N.; Magdolen, V. Quantitative reverse transcription-PCR assay for detection of mRNA encoding full length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer Clin. Chem. 2006, 52, 1070-1079
52. Shvartsman, H. S.; Lu, K. H.; Lee, J.; Lillie, J.; Deavers, M. T.; Clifford, S.; Wolf, J. K.; Mills, G. B.; Bast, R. C., Jr.; Gershenson, D. M.; Schmandt, R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas Gynecol. Oncol. 2003, 90, 44-50
53. McIntosh, M. W.; Liu, Y.; Drescher, C.; Urban, N.; Diamandis, E. P. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma Clin. Cancer Res. 2007, 13, 4422-4428
54. Planque, C.; de Monte, M.; Guyetant, S.; Rollin, J.; Desmazes, C.; Panel, V.; Lemarié, E.; Courty, Y. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer Biochem. Biophys. Res. Commun. 2005, 329, 1260-1266
55. Sher, Y. P.; Chou, C. C.; Chou, R. H.; Wu, H. M.; Chang, W. S.; Chen, C. H.; Yang, P. C.; Wu, C. W.; Yu, C. L.; Peck, K. Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness Cancer Res. 2006, 66, 11763-11770
56. Planque, C.; Aïnciburu, M.; Heuzé-Vourch, N.; Régina, S.; de Monte, M.; Courty, Y. Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues Biol Chem. 2006, 387, 783-788
57. Planque, C.; Bléchet, C.; Ayadi-Kaddour, A.; Heuzé-Vourch, N.; Dumont, P.; Guyétant, S.; Diamandis, E. P.; El Mezni, F.; Courty, Y. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung Biol. Chem. 2008, 389, 781-786
58. Petraki, C. D.; Gregorakis, A. K.; Vaslamatzis, M. M.; Papanastasiou, P. A.; Yousef, G. M.; Levesque, M. A.; Diamandis, E. P. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma Tumor Biol. 2006, 27, 1-7
59. Prezas, P.; Scorilas, A.; Yfanti, C.; Viktorov, P.; Agnanti, N.; Diamandis, E. P.; Talieri, M. The role of human tissue kallikreins 7 and 8 in intracranial malignancies Biol. Chem. 2006, 387, 1607-1612
60. Santin, A. D.; Diamandis, E. P.; Bellone, S.; Soosaipillai, A.; Cane, S.; Palmieri, M.; Burnett, A.; Roman, J. J.; Pecorelli, S. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer Clin. Cancer Res. 2005, 11, 3320-3325
61. Jin, H.; Nagai, N.; Shigemasa, K.; Gu, L.; Tanimoto, H.; Yunokawa, M.; Ohama, K.; Kudo, Y.; OBrien, T. J. Expression of tumor-associated differentially expressed gene-14 (TADG-14/KLK8) and its protein hK8 in uterine endometria and endometrial carcinomas Tumor Biol. 2006, 27, 274-282
62. Santin, A. D.; Diamandis, E. P.; Bellone, S.; Marizzoni, M.; Bandiera, E.; Palmieri, M.; Papasakelariou, C.; Katsaros, D.; Burnett, A.; Pecorelli, S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas Am. J. Obstet. Gynecol. 2006, 194, 1296-1302
63. Darling, M. R.; Jackson-Boeters, L.; Daley, T. D.; Diamandis, E. P. Human kallikrein 6 expression in salivary gland tumors J. Histochem. Cytochem. 2006, 54, 337-342
64. Darling, M. R.; Jackson-Boeters, L.; Daley, T. D.; Diamandis, E. P. Human kallikrein 13 expression in salivary gland tumors Int. J. Biol. Markers 2006, 21, 106-110
65. Klucky, B.; Mueller, R.; Vogt, I.; Teurich, S.; Hartenstein, B.; Breuhahn, K.; Flechtenmacher, C.; Angel, P.; Hess, J. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion Cancer Res. 2007, 67, 8198-8206
66. Clements, J. A. The Molecular Biology of the Kallikreins and Their Roles in Inflammation. In The Kinin System; Farmer, S. G., Ed.; Academic Press: San Diego, CA, 1997; Vol. 5, pp 71-97.
67. Bhoola, K. D.; Figueroa, C. D.; Worthy, K. Bioregulation of kinins: kallikreins, kininogens, and kininases Pharmacol. Rev. 1992, 44, 1-80
68. Oikonomopoulou, K.; Hansen, K. K.; Saifeddine, M.; Tea, I.; Blaber, M.; Blaber, S. I.; Scarisbrick, I.; Andrade-Gordon, P.; Cottrell, G. S.; Bunnett, N. W.; Diamandis, E. P.; Hollenberg, M. D. Proteinase-activated receptors, targets for kallikrein signaling J. Biol. Chem. 2006, 281, 32095-32112
69. Oikonomopoulou, K.; Hansen, K. K.; Chapman, K.; Vergnolle, N.; Diamandis, E. P.; Hollenberg, M. D. Kallikrein-mediated activation of PARs in inflammation and nociception Inflammation Res. 2007, 56, S499-S502
70. Coughlin, S. R. Protease-activated receptors in hemostasis, thrombosis and vascular biology J. Thromb. Haemostasis 2005, 3, 1800-1814
71. Steinhoff, M.; Buddenkotte, J.; Shpacovitch, V.; Rattenholl, A.; Moormann, C.; Vergnolle, N.; Luger, T. A.; Hollenberg, M. D. Proteinase-activated receptors: transducers of proteinase mediated signaling in inflammation and immune response Endocr. Rev. 2005, 26, 1-43
72. Ramachandran, R.; Hollenberg, M. D. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more Br. J. Pharmacol. 2008, 153, S263-S282
73. Vu, T.; Hung, D.; Wheaton, V.; Coughlin, S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation Cell 1991, 64, 1057-1068
74. Bohm, S.; Khitin, L.; Grady, E.; Aponte, G.; Payan, D.; Bunnett, N. Mechanisms of desensitization and resensitization of proteinase-activated receptor-2 J. Biol. Chem. 1996, 271, 22003-22016
75. Boire, A.; Covic, L.; Agarwal, A.; Jacques, S.; Sherifi, S.; Kuliopulos, A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells Cell 2005, 120, 303-313
76. Hollenberg, M. D.; Oikonomopoulou, K.; Hansen, K. K.; Saifeddine, M.; Ramachandran, R.; Diamandis, E. P. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer Biol. Chem. 2008, 389, 643-651
77. Chackalamannil, S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects J. Med. Chem. 2006, 49 (18) 5389-5403
78. Severino, B.; Santagada, V.; Perissutti, E.; Fiorino, F.; Frecentese, F.; De Angelis, F.; Esposito, A.; Caliendo, G. Recent advances in synthesis of PAR ligands as therapeutic strategy for inflammatory diseases Mini-Rev. Med. Chem. 2009, 9, 653-663
79. Ramachandran, R.; Noorbakhsh, F.; DeFea, K.; Hollenberg, M. D. Targeting proteinase-activated receptors: therapeutic potential and challenges Nat. Rev. Drug Discovery 2012, 11, 69-86
80. Landis, R. C. Protease activated receptors: clinical relevance to hemostasis and inflammation Hematol. Oncol. Clin. North Am. 2007, 21, 103-113
81. Martorell, L.; Martínez-González, J.; Rodríguez, C.; Gentile, M.; Calvayrac, O.; Badimon, L. Thrombin and protease-activated receptors (PARs) in atherothrombosis Thromb Haemostasis 2008, 99, 305-315
82. Napoli, C.; Cicala, C.; Wallace, J. L.; de Nigris, F.; Santagada, V.; Caliendo, G.; Franconi, F.; Ignarro, L. J.; Cirino, G. Protease-activated receptor-2 modulates myocardial ischemia reperfusion injury in the rat heart Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 3678-3683
83. Vergnolle, N.; Derian, C. K.; DAndrea, M. R.; Steinhoff, M.; Andrade-Gordon, P. Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4 J. Immunol. 2002, 169, 1467-1473
84. Noorbakhsh, F.; Vergnolle, N.; McArthur, J.C.; Silva, C.; Vodjgani, M.; Andrade-Gordon, P.; Hollenberg, M. D.; Power, C. Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection J. Immunol. 2005, 174, 7320-7329
85. Noorbakhsh, F.; Tsutsui, S.; Vergnolle, N.; Boven, L. A.; Shariat, N.; Vodjgani, M.; Warren, K. G.; Andrade-Gordon, P.; Hollenberg, M. D.; Power, C. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis J. Exp. Med. 2006, 203, 425-435
86. Vergnolle, N.; Hollenberg, M. D.; Wallace, J. L. Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1) Br. J. Pharmacol. 1999, 126, 1262-1268
87. Hollenberg, M. D.; Saifeddine, M.; Sandhu, S.; Houle, S.; Vergnolle, N. Proteinase activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo Br. J. Pharmacol. 2004, 143, 443-454
88. Kelso, E. B.; Lockhart, J. C.; Hembrough, T.; Dunning, L.; Plevin, R.; Hollenberg, M. D.; Sommerhoff, C. P.; McLean, J. S.; Ferrell, W. R. Therapeutic promise of proteinase activated receptor-2 antagonism in joint inflammation J. Pharmacol. Exp. Ther. 2006, 316, 1017-1024
89. Agarwal, A.; Covic, L.; Sevigny, L. M.; Kaneider, N. C.; Lazarides, K.; Azabdaftari, G.; Sharifi, S.; Kuliopulos, A. Targeting a metalloprotease-PAR-1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer Mol. Cancer Ther. 2008, 7, 2746-2757
90. Zigler, M.; Kamiya, T.; Brantley, E. C.; Villares, G. J.; Bar-Eli, M. PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis Cancer Res. 2011, 71 (21) 6561-6566
91. Kim, S. J.; Shin, J. Y.; Lee, K. D.; Bae, Y. K.; Choi, I. J.; Park, S. H.; Chun, K. H. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1(MMP-1) PLoS One 2011, 6 (9) e25103
92. Cisowski, J.; OCallaghan, K.; Kuliopulos, A.; Yang, J.; Nguyen, N.; Deng, Q.; Yang, E.; Fogel, M.; Tressel, S.; Foley, C.; Agarwal, A.; Hunt, S. W., III; McMurry, T.; Brinckerhoff, L.; Covic, L. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer Am. J. Pathol. 2011, 179 (1) 513-523
93. Yousef, G. M.; Obiezu, C. V.; Luo, L. Y.; Black, M. H.; Diamandis, E. P. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues and is hormonally regulated Cancer Res. 1999, 59, 4252-4256
94. Mize, G. J.; Wang, W.; Takayama, T. K. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2 Mol. Cancer Res. 2008, 6, 1043-1051
95. Wang, W.; Mize, G. J.; Zhang, X.; Takayama, T. K. Kallikrein- related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1 Int. J. Cancer 2010, 126, 599-610
96. Krenzer, S.; Peterziel, H.; Mauch, C.; Blaber, S. I.; Blaber, M.; Angel, P.; Hess, J. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment J. Invest. Dermatol. 2011, 131 (11) 2281-2288
97. Gratio, V.; Beaufort, N.; Seiz, L.; Maier, J.; Virca, G. D.; Debela, M.; Grebenchtchikov, N.; Magdolen, V.; Darmoul, D. Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells Am. J. Pathol. 2010, 176 (3) 1452-1461
98. Gratio, V.; Loriot, C.; Virca, G. D.; Oikonomopoulou, K.; Walker, F.; Diamandis, E. P.; Hollenberg, M. D.; Darmoul, D. Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells Am. J. Pathol. 2011, 179 (5) 2625-2636
99. Brattsand, M.; Stefansson, K.; Lundh, C.; Haasum, Y.; Egelrud, T. A proteolytic cascade of kallikreins in the stratum corneum J. Invest. Dermatol. 2005, 124, 198-203
100. Stefansson, K.; Brattsand, M.; Ny, A.; Glas, B.; Egelrud, T. Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum Biol. Chem. 2006, 387, 761-768
101. Komatsu, N.; Saijoh, K.; Sidiropoulos, M.; Tsai, B.; Levesque, M. A.; Elliott, M. B.; Takehara, K.; Diamandis, E. P. Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender J. Invest. Dermatol. 2005, 125, 1182-1189
102. Caubet, C.; Jonca, N.; Brattsand, M.; Guerrin, M.; Bernard, D.; Schmidt, R.; Egelrud, T.; Simon, M.; Serre, G. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/ hK7 J. Invest. Dermatol. 2004, 122, 1235-1244
103. Stefansson, K.; Brattsand, M.; Roosterman, D.; Kempkes, C.; Bocheva, G.; Steinhoff, M.; Egelrud, T. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases J. Invest. Dermatol. 2008, 128, 18-25
104. Hovnanian, A. Netherton syndrome: new advances in the clinic, disease mechanism and treatment Exp. Rev. Dermatol. 2012, 7 (1) 81-92
105. Briot, A.; Deraison, C.; Lacroix, M.; Bonnart, C.; Robin, A.; Besson, C.; Dubus, P.; Hovnanian, A. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome J. Exp. Med. 2009, 206, 1135-1147
106. Gao, L.; Chao, L.; Chao, J. A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor Exp. Cell Res. 2010, 316 (3) 376-389
107. Diamandis, E. P.; Yousef, G. M.; Petraki, C.; Soosaipillai, A. R. Human kallikrein 6 as a biomarker of Alzheimers disease Clin. Biochem. 2000, 33, 663-667
108. Ogawa, K.; Yamada, T.; Tsujioka, Y.; Taguchi, J.; Takahashi, M.; Tsuboi, Y.; Fujino, Y.; Nakajima, M.; Yamamoto, T.; Akatsu, H.; Mitsui, S.; Yamaguchi, N. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimers disease and Parkinsons disease Psychiatry Clin. Neurosci. 2000, 54, 419-426
109. Scarisbrick, I. A.; Linbo, R.; Vandell, A. G.; Keegan, M.; Blaber, S. I.; Blaber, M.; Sneve, D.; Lucchinetti, C. F.; Rodriguez, M.; Diamandis, E. P. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration Biol. Chem. 2008, 389, 739-745
110. Noorbakhsh, F.; Tsutsui, S.; Vergnolle, N.; Boven, L. A.; Shariat, N.; Vodjgani, M.; Warren, K. G.; Andrade-Gordon, P.; Hollenberg, M. D.; Power, C. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis J. Exp. Med. 2006, 203, 425-435
111. Vandell, A. G.; Larson, N.; Laxmikanthan, G.; Panos, M.; Blaber, S. I.; Blaber, M.; Scarisbrick, I. A. Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines J. Neurochem. 2008, 107, 855-870
112. Scarisbrick, I. A.; Epstein, B.; Cloud, B. A.; Yoon, H.; Wu, J.; Renner, D. N.; Blaber, S. I.; Blaber, M.; Vandell, A. G.; Bryson, A. L. Functional role of kallikrein 6 in regulating immune cell survival PLoS One 2011, 6 (3) e18376
113. Goettig, P.; Magdolen, V.; Brandstetter, H. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs) Biochimie 2010, 92, 1546-1567
114. Bode, W.; Huber, R. Natural protein proteinase inhibitors and their interaction with proteinases Eur. J. Biochem. 1992, 204, 433-451
115. Fritz, H.; Förg-Brey, B.; Umezawa, H.; Hoppe, S. Z. Leupeptin and antipain. Strong competitive inhibitors of sperm acrosomal proteinase (boar acrosin) and kallikreins from porcine organs (pancreas, submand. glands, urine) Physiol. Chem. 1973, 354, 1304-1306
116. Kishi, T.; Cloutier, S. M.; Kündig, C.; Deperthes, D.; Diamandis, E. P. Activation and enzymatic characterization of recombinant human kallikrein 8 Biol. Chem. 2006, 387, 723-731
117. 2+ and extracellular protease inhibitors Eur. J. Biochem. 1999, 262, 781-789
118. Debela, M.; Hess, P.; Magdolen, V.; Schechter, N. M.; Steiner, T.; Huber, R.; Bode, W.; Goettig, P. Chymotryptic specificity determinants in the 1.0 Å structure of the zinc-inhibited human tissue kallikrein 7 Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 16086-16091
119. Swedberg, J. E.; de Veer, S. J.; Harris, J. M. Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia Biol. Chem. 2010, 391, 357-374
120. Pimenta, D.; Melo, R. L.; Caliendo, G.; Santagada, V.; Fiorino, F.; Severino, B.; de Nucci, G.; Juliano, L.; Juliano, M. A. Design of inhibitors for human tissue kallikrein using nonnatural aromatic and basic amino acids Biol. Chem. 2002, 383, 853-857
121. Pimenta, D. C.; Fogac, S. E.; Melo, R. L.; Juliano, L.; Juliano, M. A. Specificity of S′1 and S′2 subsites of human tissue kallikrein using the reactive-centre loop of kallistatin: the importance of P′1 and P′2 positions in design of inhibitors Biochem. J. 2003, 371, 1021-1025
122. Hekim, C.; Leinonen, J.; Narvanen, A.; Koistinen, H.; Zhu, L.; Koivunen, E.; Vaisanen, V.; Stenman, U. H. Novel peptide inhibitors of human kallikrein 2 J. Biol. Chem. 2006, 281, 12555-12560
123. Pakkala, M.; Hekim, C.; Soininen, P.; Leinonen, J.; Koistinen, H.; Weisell, J.; Stenman, U. H.; Vepsäläinen, J.; Närvänen, A. Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors J. Pept. Sci. 2007, 13, 348-353
124. Hassan, M. I.; Kumar, V.; Somvanshi, R. K.; Dey, S.; Singh, T. P.; Yadav, S. Structure-guided design of peptidic ligand for human prostate specific antigen J. Pept. Sci. 2007, 13, 849-855
125. LeBeau, A. M.; Singh, P.; Isaacs, J. T.; Denmeade, S. R. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen Chem. Biol. 2008, 15, 665-674
126. LeBeau, A. M.; Banerjee, S. R.; Pomper, M. G.; Mease, R. C.; Denmeade, S. R. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer Bioorg. Med. Chem. 2009, 17, 4888-4893
127. Singh, P.; LeBeau, A. M.; Lilja, H.; Denmeade, S. R.; Isaacs, J. T. Molecular insights into substrate specificity of prostate specific antigen through structural modeling Proteins 2009, 77, 984-993
128. Swedberg, J. E.; Nigon, L. V.; Reid, J. C.; de Veer, S. J.; Walpole, C. M.; Stephens, C. R.; Walsh, T. P.; Takayama, T. K.; Hooper, J. D.; Clements, J. A.; Buckle, A. M.; Harris, J. M. Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4 Chem. Biol. 2009, 16, 633-643
129. Deraison, C.; Bonnart, C.; Lopez, F.; Besson, C.; Robinson, R.; Jayakumar, A.; Wagberg, F.; Brattsand, M.; Hachem, J. P.; Leonardsson, G.; Hovnanian, A. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction Mol. Biol. Cell 2007, 18, 3607-3619
130. Vasileiou, Z.; Barlos, K. K.; Gatos, D.; Adermann, K.; Deraison, C.; Barlos, K. Synthesis of the proteinase inhibitor LEKTI domain 6 by the fragment condensation method and regioselective disulfide bond formation Biopolymers 2010, 94, 339-349
131. Evans, D. M. Preparation of Aminothiazoles, Including Dipeptide [(2-Aminothiazol-5-yl)methyl]amide Derivatives, as Kallikrein 1 Inhibitors. Patent Appl. WO 2011051673, 2011.
132. Evans, D. M.; Allan, C. E. Preparation of Azaindoles, Including Dipeptide [(1 H -Pyrrolo[2,3- b ]pyridin-5-yl)methyl]amide Derivatives, as Kallikrein 1 Inhibitors. Patent Appl. WO2011051672, 2011.
133. Evans, D. M.; Allan, C. E.; Horton, J.; Rooker, D. P. Preparation of Dipeptide [(6-Aminopyridin-3-yl)methyl]amide Derivatives as Kallikrein 1 Inhibitors. Patent. Appl. WO2009133348, 2009.
134. Koistinen, H.; Wohlfahrt, G.; Mattsson, J. M.; Wu, P.; Lahdenperä, J.; Stenman, U. H. Novel small molecule inhibitors for prostate-specific antigen Prostate 2008, 68, 1143-1151
135. Teixeira, T. S. P.; Freitas, R. F.; Abrahao, O., Jr.; Devienne, K. F.; de Souza, L. R.; Blaber, S. I.; Blaber, M.; Kondo, M. Y.; Juliano, M. A.; Juliano, L.; Puzer, L. Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7 Bioorg. Med. Chem. Lett. 2011, 21, 6112-6115
136. Andrade-Gordon, P.; Maryanoff, B. E.; Derian, C. K.; Zhang, H. C.; Addo, M. F.; Darrow, A. L.; Eckardt, A. J.; Hoekstra, W. J.; McComsey, D. F.; Oksenberg, D.; Reynolds, E. E.; Santulli, R. J.; Scarborough, R. M.; Smith, C. E.; White, K. B. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 12257-12262
137. Zhang, H. C.; White, K. B.; McComsey, D. F.; Addo, M. F.; Andrade-Gordon, P.; Derian, C. K.; Oksenberg, D.; Maryanoff, B. E. High affinity thrombin receptor (PAR-1) ligands: a new generation of indole-based peptide mimetic antagonists with a basic amine at the C-terminus Bioorg. Med. Chem. Lett. 2003, 13, 2199-2203
138. Zhang, H. C.; Derian, C. K.; Andrade-Gordon, P.; Hoekstra, W. J.; McComsey, D. F.; White, K. B.; Poulter, B. L.; Addo, M. F.; Cheung, W. M.; Damiano, B. P.; Oksenberg, D.; Reynolds, E. E.; Pandey, A.; Scarborough, R. M.; Maryanoff, B. Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates J. Med. Chem. 2001, 44, 1021-1024
139. Severino, B.; Fiorino, F.; Perissutti, E.; Frecentese, F.; Cirino, G.; Roviezzo, F.; Santagada, V.; Caliendo, G. Synthesis and pharmacological evaluation of peptide-mimetic protease-activated receptor-1 antagonists containing novel heterocyclic scaffolds Bioorg. Med. Chem. 2008, 16, 6009-6020
140. Covic, L.; Gresser, A. L.; Talavera, J.; Swift, S.; Kuliopulos, A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane tethered peptides Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 643-648
141. Covic, L.; Misra, M.; Badar, J.; Singh, C.; Kuliopulos, A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation Nat. Med. 2002, 8, 1161-1165
142. Ahn, H. S.; Arik, L.; Boykow, G.; Burnett, D.; Caplen, M. A.; Czarniecki, M.; Domalski, M.; Foster, C.; Manna, M.; Stamford, A. W.; Wu, Y. Structure-activity relationships of pyrazoloquinazolones as thrombin receptor antagonists Bioorg. Med. Chem. Lett. 1999, 9, 2073-2078
143. Strande, J. L.; Hsu, A.; Su, J.; Fu, X.; Gross, G. J.; Baker, J. E. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts Basic Res. Cardiol. 2007, 102, 350-358
144. Zania, P.; Kritikou, S.; Flordellis, C. S.; Maragoudakis, M. E.; Tsopanoglou, N. E. Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis J. Pharmacol. Exp. Ther. 2006, 318, 246-254
145. Di Serio, C.; Pellerito, S.; Duarte, M.; Massi, D.; Naldini, A.; Cirino, G.; Prudovsky, I.; Cantucci, M.; Geppetti, P.; Marchionni, N.; Casotti, G.; Tarantini, F. Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism Basic Clin. Pharmacol. Toxicol. 2007, 101, 63-69
146. ODonoghue, M. L.; Bhatt, D. L.; Wiviott, S. D.; Goodman, S. G.; Fitzgerald, D. J.; Angiolillo, D. J.; Goto, S.; Montalescot, G.; Zeymer, U.; Aylward, P. E.; Guetta, V.; Dudek, D.; Ziecina, R.; Contant, C. F.; Flather, M. D. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial Circulation 2011, 123, 1843-1853
147. Wiviott, S. D.; Flather, M. D.; ODonoghue, M. L.; Goto, S.; Fitzgerald, D. J.; Cura, F.; Aylward, P.; Guetta, V.; Dudek, D.; Contant, C. F.; Angiolillo, D. J.; Bhatt, D. L. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial Circulation 2011, 123, 1854-1863
148. Chackalamannil, S.; Xia, Y.; Greenlee, W. J.; Clasby, M.; Doller, D.; Tsai, H.; Asberom, T.; Czarniecki, M.; Ahn, H. S.; Boykow, G.; Foster, C.; Agans-Fantuzzi, J.; Bryant, M.; Lau, J.; Chintala, M. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents J. Med. Chem. 2005, 48, 5884-5887
149. Xia, Y.; Chackalamannil, S.; Chan, T. M.; Czarniecki, M.; Doller, D.; Eagen, K.; Greenlee, W. J.; Tsai, H.; Wang, Y.; Ahn, H. S.; Boykow, G. C.; McPhail, A. T. Himbacine derived thrombin receptor (PAR-1) antagonists: structure-activity relationship of the lactone ring Bioorg. Med. Chem. Lett. 2006, 16, 4969-4972
150. Xia, Y.; Chackalamannil, S.; Clasby, M.; Doller, D.; Eagen, K.; Greenlee, W. J.; Tsai, H.; Agans-Fantuzzi, J.; Ahn, H. S.; Boykow, G. C.; Hsieh, Y.; Lunn, C. A.; Chintala, M. Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring Bioorg. Med. Chem. Lett. 2007, 17, 4509-4513
151. Clasby, M. C.; Chackalamannil, S.; Czarniecki, M.; Doller, D.; Eagen, K.; Greenlee, W. J.; Lin, Y.; Tsai, H.; Xia, Y.; Ahn, H. S.; Agans-Fantuzzi, J.; Boykow, G.; Chintala, M.; Foster, C.; Bryant, M.; Lau, J. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists Bioorg. Med. Chem. Lett. 2006, 16, 1544-1548
152. Clasby, M. C.; Chackalamannil, S.; Czarniecki, M.; Doller, D.; Eagen, K.; Greenlee, W. J.; Lin, Y.; Tagat, J. R.; Tsai, H.; Xia, Y.; Ahn, H. S.; Agans-Fantuzzi, J.; Boykow, G.; Chintala, M.; Hsieh, Y.; McPhail, A. T. Himbacine derived thrombin receptor antagonists: discovery of a new tricyclic core Bioorg. Med. Chem. Lett. 2007, 17, 3647-3651
153. Chelliah, M. V.; Chackalamannil, S.; Xia, Y.; Eagen, K.; Clasby, M. C.; Gao, X.; Greenlee, W. J.; Ahn, H. S.; Agans-Fantuzzi, J.; Boykow, G.; Hsieh, Y.; Bryant, M.; Palamanda, J.; Chan, T. M.; Hesk, D.; Chintala, M. Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists J. Med. Chem. 2007, 50, 5147-5160
154. Chackalamannil, S.; Wang, Y.; Greenlee, W. J.; Hu, Z.; Xia, Y.; Ahn, H. S.; Boykow, G.; Hsieh, Y.; Palamanda, J.; Agans-Fantuzzi, J.; Kurowski, S.; Graziano, M.; Chintala, M. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity J. Med. Chem. 2008, 51, 3061-3064
155. Becker, R. C.; Moliterno, D. J.; Jennings, L. K.; Pieper, K. S.; Pei, J.; Niederman, A.; Ziada, K. M.; Berman, G.; Strony, J.; Joseph, D.; Mahaffey, K. W.; Van de Werf, F.; Veltri, E.; Harrington, R. A. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 2009, 14, 919-928
156. The TRA·CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA·CER) trial: study design and rationale Am. Heart J. 2009, 158, 327-334
157. Morrow, D.; Scirica, B.; Fox, K. A. A.; Berman, G.; Strony, J.; Veltri, E.; Bonaca, M. P.; Fish, P.; McCabe, C. H.; Braunwald, E. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2°P)-TIMI 50 trial Am. Heart J. 2009, 158, 335-341
158. Xia, Y.; Chackalamannil, S.; Greenlee, W. J.; Wang, Y.; Hu, Z.; Root, Y.; Wong, J.; Kong, J.; Ahn, H. S.; Boykow, G.; Hsieh, Y.; Kurowski, S.; Chintala, M. Discovery of a vorapaxar analog with increased aqueous solubility Bioorg. Med. Chem. Lett. 2010, 20, 6676-6679
159. Perez, M.; Lamothe, M.; Maraval, C.; Mirabel, E.; Loubat, C.; Planty, B.; Horn, C.; Michaux, J.; Letienne, R.; Pignier, C. B. A.; Nadal-Wollbold, F.; Cussac, D.; De Vries, L.; Le Grand, B. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo J. Med. Chem. 2009, 52, 5826-5836
160. Letienne, R.; Leparq-Panissie, A.; Calmettes, Y.; Nadal-Wollbold, F.; Perez, M.; Le Grand, B. Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat Biochem. Pharmacol. 2010, 79, 1616-1621
161. Chieng-Yane, P.; Bocquet, A.; Letienne, R.; Bourbon, T.; Sablayrolles, S.; Perez, M.; Hatem, S. N.; Lompre, A. M.; Le Grand, B.; David-Dufilho, M. Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor α and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells J. Pharmacol. Exp. Ther. 2011, 336, 643-651
162. Rilatt, I.; Mirabel, E.; Le Grand, B.; Perez, M. Discovery and SAR of small molecule PAR1 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 903-906
163. Planty, B.; Pujol, C.; Lamothe, M.; Maraval, C.; Horn, C.; Le Grand, B.; Perez, M. Exploration of a new series of PAR1 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 1735-1739
164. Hansen, K. K.; Sherman, P. M.; Cellars, L.; Andrade-Gordon, P.; Pan, Z.; Baruch, A.; Wallace, J. L.; Hollenberg, M. D.; Vergnolle, N. A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 8363-8368
165. Kanke, T.; Ishiwata, H.; Kabeya, M.; Saka, M.; Doi, T.; Hattori, Y.; Kawabata, A.; Plevin, R. 2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice Br. J. Pharmacol. 2005, 144 (2) 212-219
166. McGuire, J. J.; Saifeddine, M.; Triggle, C. R.; Sun, K.; Hollenberg, M. D. 2-Furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist J. Pharmacol. Exp. Ther. 2004, 309, 1124-1131
167. Barry, G. D.; Suen, J. Y.; Le, G. T.; Cotterell, A.; Reid, R. C.; Fairlie, D. P. Novel agonists and antagonists for human protease activated receptor 2 J. Med. Chem. 2010, 53, 7428-7440
168. Boitano, S.; Flynn, A. N.; Schulz, S. M.; Hoffman, J.; Price, T. J.; Vagner, J. Potent agonists of the protease activated receptor 2 (PAR2) J. Med. Chem. 2011, 54, 1308-1313
169. 2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo J. Biol. Chem. 2011, 286 (21) 19076-190788
170. Kanke, T.; Kabeya, M.; Kubo, S.; Kondo, S.; Yasuoka, K.; Tagashira, J.; Ishiwata, H.; Saka, M.; Furuyama, T.; Nishiyama, T.; Doi, T.; Hattori, Y.; Kawabata, A.; Cunningham, M. R.; Plevin, R. Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo Br. J. Pharmacol. 2009, 158, 361-371
171. Goh, F. G.; Ng, P. Y.; Nilsson, M.; Kanke, T.; Plevin, R. Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling Br. J. Pharmacol. 2009, 158, 1695-1704
172. Suen, J. Y.; Barry, G. D.; Lohman, R. J.; Halili, M. A.; Cotterell, A. J.; Le, G. T.; Fairlie, D. P. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110) Br. J. Pharmacol. 2012, 165 (5) 1413-1423
173. Lohman, R. J.; Cotterell, A. J.; Suen, J.; Liu, L.; Do, T. A.; Vesey, D. A.; Fairlie, D. P. Antagonism of protease activated receptor 2 protects against experimental colitis J. Pharmacol. Exp. Ther. 2012, 340, 256-265
174. Seitzberg, J. G.; Knapp, A. E.; Winther Lund, B.; Mandrup Bertozzi, S.; Currier, E. A.; Ma, J.; Sherbukhin, V.; Burstein, E. S.; Olsson, R. Discovery of potent and selective small-molecule PAR-2 agonists J. Med. Chem. 2008, 51, 5490-5493
175. Gardell, L. R.; Ma, J. N.; Seitzberg, J. G.; Knapp, A. E.; Schiffer, H. H.; Tabatabaei, A.; Davis, C.; Wong, K. K.; Lund, B. W.; Nash, N. R.; Gao, Y.; Lameh, J.; Schmelzer, K.; Olsson, R.; Burstein, E. S. Identification and characterization of novel small-molecule protease-activated receptor 2 agonists J. Pharmacol. Exp. Ther. 2008, 327, 799-808
176. Wu, C. C.; Huang, S. W.; Hwang, T. L.; Kuo, S. C.; Lee, F. Y.; Teng, C. M. YD-3, a novel inhibitor of protease-induced platelet activation Br. J. Pharmacol. 2000, 130, 1289-1296
177. Wielders, S. J.; Bennaghmouch, A.; Reutelingsperger, C. P.; Bevers, E. M.; Lindhout, T. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists J. Thromb. Haemostasis 2007, 5, 571-576
178. Strande, J. L.; Hsu, A.; Su, J.; Fu, X.; Gross, G. J.; Baker, J. E. Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signalling J. Pharmacol. Exp. Ther. 2008, 324 (3) 1045-1054
179. Slofstra, S. H.; Bijlsma, M. F.; Groot, A. P.; Reitsma, P. H.; Lindhout, T.; Cate, H.; Spek, C. A. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation Blood 2007, 110 (9) 3176-3182